ArticleThe Journal of allergy and clinical immunology2009
Lung mast cells are a source of secreted phospholipases A2.
Article in The Journal of allergy and clinical immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.BMC pediatrics · 2011Trial
- CD1a and skin T cells: a pathway for therapeutic intervention.Clinical and experimental dermatology · 2024Review
- Article
- Functional Modulation of Human Macrophages by Secreted Phospholipases ABiomedicines · 2022Review
- The interaction of secreted phospholipase A2-IIA with the microbiota alters its lipidome and promotes inflammation.JCI insight · 2022Article
- Regulatory Roles of Phospholipase AFrontiers in immunology · 2022Review
- Choline chloride attenuates the allergic airway disease by inhibiting the lysophosphatidylcholine induced response in mouse model.Current research in pharmacology and drug discovery · 2022Article
- Roles of Immune Cells in Hereditary Angioedema.Clinical reviews in allergy & immunology · 2021Review
- Emerging Role of Phospholipase-Derived Cleavage Products in Regulating Eosinophil Activity: Focus on Lysophospholipids, Polyunsaturated Fatty Acids and Eicosanoids.International journal of molecular sciences · 2021Review
- Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase AJournal of clinical medicine · 2020Article
- Article
- Group IID, IIE, IIF and III secreted phospholipase ABiochimica et biophysica acta. Molecular and cell biology of lipids · 2019Review
- Review
- Combining 3D graphene-like screen-printed carbon electrode with methylene blue-loaded liposomal nanoprobes for phospholipase ABiosensors & bioelectronics · 2019Article
- Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, andJournal of immunology research · 2019Article
- Secreted Phospholipases AFrontiers in immunology · 2018Article
- Group V Secreted Phospholipase AFrontiers in immunology · 2017Article
- Potential Metabolic Biomarkers to Identify Interstitial Lung Abnormalities.International journal of molecular sciences · 2016Article
- Lysophosphatidylcholine plays critical role in allergic airway disease manifestation.Scientific reports · 2016Article
- Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase.Science translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSecreted phospholipases A(2) (sPLA(2)s) are released in plasma and other biologic fluids of patients with inflammatory, autoimmune, and allergic diseases.
objectiveWe sought to evaluate sPLA(2) activity in the bronchoalveolar lavage fluid (BALF) of asthmatic patients and to examine the expression and release of sPLA(2)s from primary human lung mast cells (HLMCs).
methodssPLA(2) activity was measured in BALF and supernatants of either unstimulated or anti-IgE-activated HLMCs as hydrolysis of oleic acid from radiolabeled Escherichia coli membranes. Expression of sPLA(2)s was examined by using RT-PCR. The release of cysteinyl leukotriene (LT) C(4) was measured by means of enzyme immunoassay.
resultsPhospholipase A(2) (PLA(2)) activity was higher in the BALF of asthmatic patients than in the control group. BALF PLA(2) activity was blocked by the sPLA(2) inhibitors dithiothreitol and Me-Indoxam but not by the cytosolic PLA(2) inhibitor AZ-1. HLMCs spontaneously released a PLA(2) activity that was increased on stimulation with anti-IgE. This PLA(2) activity was blocked by dithiothreitol and Me-Indoxam but not by AZ-1. HLMCs constitutively express mRNA for group IB, IIA, IID, IIE, IIF, III, V, X, XIIA, and XIIB sPLA(2)s. Anti-IgE did not modify the expression of sPLA(2)s. The cell-impermeable inhibitor Me-Indoxam significantly reduced (up to 40%) the production of LTC(4) from anti-IgE-stimulated HLMCs.
conclusionssPLA(2) activity is increased in the airways of asthmatic patients. HLMCs express multiple sPLA(2)s and release 1 or more of them when activated by anti-IgE. The sPLA(2)s released by mast cells contribute to LTC(4) production by acting in an autocrine fashion. Mast cells can be a source of sPLA(2)s in the airways of asthmatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.